Lewy bodies are the pathological hallmark of Parkinson's disease (PD). While fibrillar α-synuclein (αS) is the main protein component of Lewy bodies, these structures also contain lipids. To elucidate the presence of lipids in Lewy bodies, we investigated the interaction of lipids with monomeric and fibrillar αS. In vitro, lipid membranes accelerated αS fibril formation under physiological conditions. Moreover lipids and small vesicles co-localized with supra-fibrillar structures and individual αS fibrils suggesting that aggregation initiates at the membrane. The presence of lipids in Lewy bodies may therefore be an indication that cell membranes are the major target in aggregation induced neuronal cell deat
alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles ...
Amyloid deposits from several human diseases have been found to contain membrane lipids. Co-aggregat...
α-Synuclein is a membrane-interacting protein involved in Parkinson’s disease. Here we have investig...
Lewy bodies are the pathological hallmark of Parkinson's disease (PD). While fibrillar α-synuclein (...
Intracellular α-synuclein deposits, known as Lewy bodies, have been linked to a range of neurodegene...
α-Synuclein is the major component of Lewy body inclusions found in the brains of Parkinson\u27s dis...
Parkinson's disease, the most common age-related movement disorder, is a progressive neurodegenerati...
α-synuclein is an intrinsically disordered protein implicated in synaptic vesicle trafficking at the...
BACKGROUND: Lewy body in the substantia nigra is a cardinal pathological feature of Parkinson's dise...
Background: Lewy body in the substantia nigra is a cardinal pathological feature of Parkinson’s dise...
Lewy body in the substantia nigra is a cardinal pathological feature of Parkinson's disease. Despite...
Accumulation of the protein α-synuclein into insoluble intracellular deposits termed Lewy bodies (LB...
α-synuclein misfolding and aggregation into fibrils is a common feature of α-synucleinopathies, such...
Aggregated α-synuclein in Lewy bodies is one of the hallmarks of Parkinson's disease (PD). Earlier o...
Parkinson's disease is characterised by the presence in brain tissue of aberrant inclusions known as...
alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles ...
Amyloid deposits from several human diseases have been found to contain membrane lipids. Co-aggregat...
α-Synuclein is a membrane-interacting protein involved in Parkinson’s disease. Here we have investig...
Lewy bodies are the pathological hallmark of Parkinson's disease (PD). While fibrillar α-synuclein (...
Intracellular α-synuclein deposits, known as Lewy bodies, have been linked to a range of neurodegene...
α-Synuclein is the major component of Lewy body inclusions found in the brains of Parkinson\u27s dis...
Parkinson's disease, the most common age-related movement disorder, is a progressive neurodegenerati...
α-synuclein is an intrinsically disordered protein implicated in synaptic vesicle trafficking at the...
BACKGROUND: Lewy body in the substantia nigra is a cardinal pathological feature of Parkinson's dise...
Background: Lewy body in the substantia nigra is a cardinal pathological feature of Parkinson’s dise...
Lewy body in the substantia nigra is a cardinal pathological feature of Parkinson's disease. Despite...
Accumulation of the protein α-synuclein into insoluble intracellular deposits termed Lewy bodies (LB...
α-synuclein misfolding and aggregation into fibrils is a common feature of α-synucleinopathies, such...
Aggregated α-synuclein in Lewy bodies is one of the hallmarks of Parkinson's disease (PD). Earlier o...
Parkinson's disease is characterised by the presence in brain tissue of aberrant inclusions known as...
alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles ...
Amyloid deposits from several human diseases have been found to contain membrane lipids. Co-aggregat...
α-Synuclein is a membrane-interacting protein involved in Parkinson’s disease. Here we have investig...